|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Pittsburgh |
|---|---|
| Information provided by: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00519025 |
Purpose
This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
| Condition |
|---|
|
Linezolid Resistance Staphylococcus Aureus |
| Study Type: | Observational |
| Study Design: | Cohort, Retrospective |
| Official Title: | Risk Factors for Linezolid Resistance in Staphylococcus Aureus |
| Estimated Enrollment: | 360 |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | December 2013 |
This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
linezolid resistance to staph aureus
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Brian Potoski, PharmD | 412-648-6487 | potoskiba@upmc.edu |
| Contact: Diana Lynn Pakstis, RN, BSN | 412-648-6553 | pakstisdl@dom.pitt.edu |
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Brian Potoski, PharmD 412-648-6487 potoskiba@upmc.edu | |
| Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu | |
| Principal Investigator: Brian Potoski, PharmD | |
| Principal Investigator: | Brian Potoski, PharmD | University of Pittsburgh |
More Information
| Responsible Party: | UPMC ( Brian Potoski, Pharm D ) |
| Study ID Numbers: | PRO07080006, investigator funding |
| Study First Received: | August 17, 2007 |
| Last Updated: | December 2, 2009 |
| ClinicalTrials.gov Identifier: | NCT00519025 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Linezolid Staphylococcus Aureus Infections |
|
Bacterial Infections Protein Synthesis Inhibitors Anti-Infective Agents Staphylococcal Infections Gram-Positive Bacterial Infections |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Enzyme Inhibitors Linezolid Pharmacologic Actions |
